Ways for older adults to reduce stress
April is Stress Awareness Month. Successful Aging expert Linda Pritchett shares six ways for older adults to reduce stress.
You can contact Linda Pritchett at (336) 292-3875 or visit her website here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Rhythm Express Named by Inc. Magazine as One of the Fastest Growing Private Firms in America
MINNEAPOLIS--(BUSINESS WIRE)-- VivaQuant, Inc. d.b.a. Rhythm Express, a leader in remote cardiac monitoring and digital health solutions, has been recognized as one of the fastest-growing private companies in the United States by Inc. Magazine for the third consecutive year, ranking #331. VivaQuant's continued recognition reflects the company's momentum in reshaping the future of cardiac care through intelligent remote monitoring technologies. 'We are proud of the accomplishments of our team. This is a tremendous honor to make this prestigious list for the third consecutive year. It's a powerful validation of the work we're doing to make cardiac care more accessible, efficient and effective,' said Brian Brockway, CEO of VivaQuant. 'This milestone belongs to our entire team and the providers and patients who trust our solutions every day. We're proud to be driving meaningful change in patient outcomes through our Rhythm Express business and cutting-edge monitoring technologies.' 'This milestone belongs to our entire team and the providers and patients who trust our solutions every day.' — Brian Brockway, CEO Share Innovating the Future of Remote Cardiac Monitoring VivaQuant's flagship offering, Rhythm Express, delivers advanced, near-real time cardiac diagnostics via the small, one-piece, cellular enabled RX-1 mini ™ wearable device and Rhythm Access Portal™. The platform is designed to meet the growing demand for accurate, scalable and user-friendly remote cardiac monitoring services. With a continued focus on innovation and clinical excellence, VivaQuant is well-positioned to lead the next generation of digital cardiovascular care. About VivaQuant, Inc. VivaQuant, Inc. is a digital health company specializing in remote cardiac monitoring and diagnostic services. Through its Rhythm Express platform, VivaQuant combines cutting-edge wearable technology, enhanced proprietary noise removal & analytics, and clinical insight to support better outcomes for patients and providers nationwide.
Business Wire
3 hours ago
- Business Wire
Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa™ SI Fusion System
AUSTIN, Texas--(BUSINESS WIRE)--Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa™ Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a major breakthrough in addressing sacroiliac joint dysfunction with enhanced biomechanical stability and procedural efficiency. Designed to be implanted using a posterior, minimally invasive technique, panaSIa provides joint fixation through controlled expansion across the ilium and sacrum, offering immediate mechanical stability while preserving surrounding tissue. The implant's integrated graft chamber allows for post-expansion bone grafting without disengaging instrumentation, facilitating optimal fusion conditions and minimizing procedural complexity. The first U.S. procedures are part of a limited commercial release taking place at select surgical centers ahead of full launch in Q4 2025. 'panaSIa is unlike any SI fusion device currently available,' said Aaron Calodney, MD, a nationally recognized leader in interventional pain medicine. 'The implant expands to eliminate micro-motion, providing immediate stabilization. By slightly distracting the joint space, it may reduce pain by removing contact between the arthritic surfaces. It's simple, elegant, and biomechanically sound—a truly next-generation solution for SI joint fusion.' The panaSIa system expands Wenzel Spine's portfolio of stand-alone expandable fusion technologies and reflects the company's long-term commitment to minimally invasive innovation and surgeon-driven design. 'This launch is a defining milestone for Wenzel Spine,' said William Wilson, CEO of Wenzel Spine. 'Our team has spent nearly two decades perfecting expandable device design, and panaSIa brings that legacy to a new clinical segment. We are proud to offer providers a differentiated, minimally invasive solution that transforms SI joint fusion with precision, control, and speed.' About panaSIa™ SI Fusion System The panaSIa SI Fusion System is a posteriorly placed, expandable implant that transfixes the ilium and sacrum to immobilize the SI joint and promote fusion. It is offered in two sizes allowing for anatomical customization, while its streamlined instrumentation enables true MIS placement. The integrated expansion mechanism and post-expansion graft delivery system simplify the workflow and reduce operative time. panaSIa is available now in limited release and will be widely available in Q4 2025. About Wenzel Spine, Inc. Headquartered in Austin, Texas, Wenzel Spine, Inc. is a privately held medical technology company committed to advancing the standard of care for spinal disorders through minimally invasive surgical innovation and data-driven solutions. Wenzel Spine's technologies are used by leading spine and pain physicians across the country to streamline surgical procedures and improve patient outcomes. To learn more, visit:
Yahoo
4 hours ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
